Chinese ‘Easter Eggs’ fall back to earth after wild year on Wall Street
Shares of Here Group, Zepp Health, Burning Rock Biotech and So-Young International all posted meteoric gains last year, but have given most of that back in 2026 Key Takeaways: A…
Neglected Burning Rock charms investors with high margins, narrowing losses
The cancer diagnostics company’s revenue rose slightly in the third quarter, as its gross margin rose by nearly 4 percentage points Key Takeaways: Burning Rock’s revenue rose 2.3% in the…
BRIEF: Burning Rock returns to revenue growth as loss narrows
Cancer screening company Burning Rock Biotech Ltd. (BNR.US) on Wednesday reported its revenue rose 0.8% in the third quarter year-on-year to 128.6 million yuan ($17.6 million), as it returned to…
Sinking Burning Rock faces de-listing. But could privatization bid come first?
The cancer-screening products maker is in danger of being forcibly delisted due to its sinking stock price, as income from its former top revenue source tumbles amid an industry crackdown…
FAST NEWS: Burning Rock’s cancer test gets breakthrough designation
The latest: Cancer screening company Burning Rock Biotech Ltd. (BNR.US) announced Sunday that its OverC multi-cancer detection blood test (MCDBT) has been granted breakthrough device designation by the China National…
Burning Rock narrows losses with drug research as new driver
The cancer testing company has finally reduced the flow of red ink and is generating a growing income stream from drug research services Key Takeaways: Burning Rock's net loss…
Burning Rock Localizes as Investors Grow Impatient
Cancer testing company reported a widening loss in the first quarter as it spent heavily to build up its localized business model of providing services through partner hospitals Key Takeaways:…
RELATED ARTICLES
-
U.S. tries ‘monkey scaring’ to rid Wall Street of suspicious Chinese listings
- What listings? Small Chinese firms withdraw their Wall Street IPO applications
-
Faded AI beauty: After superstar debut Nuobikan falls back to earth
2635.HK
- Chinese medicine firm seeks elusive elixir of IPO success
-
Tongcheng’s rosy report fails to discuss the worrisome elephant in its house
0780.HK
